Antipsychotic-induced weight gain is a major management problem for clinicians. It has
been shown that weight gain and obesity lead to increased cardiovascular and …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Objective Development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and the American College of …

These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia …

One of the most widely used guides to prescribing psychiatric medications, the Tenth Edition
of Maudsley Prescribing Guidelines returns with fully updated content and new sections on …

Excess deaths from cardiovascular disease are a major contributor to the significant
reduction in life expectancy experienced by people with schizophrenia. Important risk factors …

People with serious mental illness (SMI) have mortality rates 2 to 3 times higher than the
overall US population, largely due to cardiovascular disease. The prevalence of …

Background: Antipsychotic-induced metabolic adversities are often difficult to manage.
Using concomitant medications to counteract these adversities may be a rational option …

Metabolic syndrome with the atypical antipsychotics : Current Opinion in Endocrinology,
Diabetes and Obesity Metabolic syndrome with the atypical antipsychotics : Current Opinion in …

Background. When schizophrenia patients have insufficient response to clozapine,
pharmacological augmentation is often applied. This meta-analysis summarizes available …